MedPath

The expression of Transient receptor potential melastatintype 2(TRPM2) in the immunocytes of sepsis patients and the role of TRPM2 in the development of sepsis

Not Applicable
Recruiting
Conditions
sepsis
Inflammatory and Immune System - Other inflammatory or immune system disorders
Registration Number
ACTRN12612001114831
Lead Sponsor
Xiangming Fang
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

sepsis patients including sepsis, severe sepsis and sepsis shock patients.

Exclusion Criteria

Not sepsis patients

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To detect the expression of TRPM2 Messenger ribonucleic acid (mRNA) in the monocyte by using real-time Polymerase Chain Reaction (PCR).[Within 24 hours after the diagnosis of sepsis in Intensive Care Unit (ICU). We only draw blood from the sepsis patients once.];To detect the expression of TRPM2 mRNA in the lymphocyte by using real-time PCR.[Within 24 hours after the diagnosis of sepsis in Intensive Care Unit (ICU). We only draw blood from the sepsis patients once.]
Secondary Outcome Measures
NameTimeMethod
infammatory cytokines (TNFa, IL-6, IL-8, IL-10) in the plasma of sepsis patients[Within 24 hours after the diagnosis of sepsis in ICU. We only draw blood from the sepsis patients once.];To detect immunocyte apoptosis in sepsis patients by using flow cytometer.[Within 24 hours after the diagnosis of sepsis in ICU. We only draw blood from the sepsis patients once.];To assess the physiology and health of patients by using acute physiology and chronic health evaluation (APACHE )score.<br><br>Using sepsis-related Organ Failure (SOFA) score, the organ damage of sepsis patients will be assessed.[Within 24 hours after the diagnosis of sepsis in ICU. We assess the scores only once.]
© Copyright 2025. All Rights Reserved by MedPath